12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oral rigosertib: Phase I started

SymBio began an open-label, dose-escalation, Japanese Phase I trial to evaluate 280 and 560 mg oral rigosertib twice daily for the first 14 days of a 21-day cycle for about 6 cycles in MDS patients who failed, were intolerant to or progressed after treatment with chemotherapy...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >